1.0株式会社タイガメッドジャパンhttps://tigermedjp.comdigitalcubehttps://tigermedjp.com/news/author/digitalcube/rich600338<blockquote class="wp-embedded-content" data-secret="PmVIH40Bel"><a href="https://tigermedjp.com/en/about_us/corporate_charter/">Corporate Charter</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://tigermedjp.com/en/about_us/corporate_charter/embed/#?secret=PmVIH40Bel" width="600" height="338" title="“Corporate Charter” — 株式会社タイガメッドジャパン" data-secret="PmVIH40Bel" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://tigermedjp.com/wp-includes/js/wp-embed.min.js </script> Tigermed Japan, Inc. is entering the next stage of growth in its CRO business in Japan under a new management structure.In recent years, collaboration with global partners has become increasingly important in the Japanese CRO industry, alongside growing demand for the global expansion of Japanese companies. We view these trends as significant growth opportunities and are committed to further strengthening our presence in Japan while promoting the creation of value originating from Japan. Building on the knowledge, quality, and talent cultivated in Japan, we actively support the entry of Japanese companies into global markets and the advancement of their development initiatives. At the same time, we will create development and investment opportunities connecting Japan and global markets, thereby realizing a bidirectional cycle of value creation.This initiative goes beyond conventional outsourcing services; it is an effort to extend the advanced technologies and development capabilities of Japanese companies to high-growth markets worldwide and to generate new value in healthcare.With a strong sense of responsibility and pride as a CRO in Japan, we prioritize transparency, quality, and compliance, and strive to contribute to the development of pharmaceuticals and medical devices globally.https://tigermedjp.com/wp-content/uploads/2026/06/tigermed-japan_thumbnail.jpg24001260